Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood.

Slides:



Advertisements
Similar presentations
Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation  Patricia M. Sheean,
Advertisements

High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1) 
Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates  Ian Nivison-Smith, Judy M. Simpson, Anthony.
Ulas D. Bayraktar, Denái R. Milton, Elizabeth J
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
How to Treat MDS without Stem Cell Transplantation
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation  David Stephen Shulman, Wendy B. London, Dongjing.
Utility of Comorbidity Assessment in Predicting Transplantation-Related Toxicity Following Autologous Hematopoietic Stem Cell Transplantation for Multiple.
Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin’s Lymphoma (HL) in the ABVD Therapeutic Era  Sarah F. Keller,
The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.
Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization  Ivana N.M. Micallef,
Volume 15, Issue 8, Pages (July 2014)
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.
Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront.
Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation  Patricia M. Sheean,
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Sabina Kersting, Leo F. Verdonck 
Efficacy of Reduced-Intensity Allogeneic Stem Cell Transplantation in Chemotherapy- Refractory Non-Hodgkin Lymphoma  Robert M. Dean, Daniel H. Fowler,
Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children’s Oncology Group Study A5962 
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
Favorable Outcome for Infant Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation  David A. Jacobsohn, Brad Hewlett, Elaine Morgan,
Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
A Process to Facilitate Decision Making in Pediatric Stem Cell Transplantation: The Individualized Care Planning and Coordination Model  Justin N. Baker,
Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma  Jessica Rueff, Michael Medinger,
Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation  Vijaya.
The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.
Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma:
Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients.
John Kuruvilla, John D. Shepherd, Heather J. Sutherland, Thomas J
HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease  Anna B. Pawlowska, Jerry C. Cheng,
Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation  Betul Oran, John E. Wagner, Todd.
Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L
Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation 
Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis  Nicolas Novitzky, Valda.
Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple.
Kamal Kant Singh Abbi, Junting Zheng, Sean M
Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma  Christopher Parrish, Amin Rahemtulla, Jim.
Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study.
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma 
Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma  Dharshan Sivaraj, Michael.
Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis  Jason.
Trajectories of Quality of Life after Hematopoietic Cell Transplantation: Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network 0902.
Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation  Rachel B. Salit, Filippo.
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation  Mohammed M. Elayan, Justin G.
What is quality in a transplant program?
Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution  William B. Ershler, Andrew S. Artz, Evan T. Keller 
Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.
Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond  Stanley R. Riddell, Michael C. Jensen, Carl.
Blood and Marrow Transplant Handbook
Bernard Maybury, Gordon Cook, Guy Pratt, Kwee Yong, Karthik Ramasamy 
Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.
Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma  Mark A. Fiala, Joseph D. Finney, Keith.
Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood.
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Addition of Plerixafor to Mobilization Regimens in Autologous Peripheral Blood Stem Cell Transplants Does Not Affect the Correlation of Preharvest Hematopoietic.
Treatment versus Transplant for Challenging Hematologic Disorders
Adult Recipients of Matched Related Donor Blood Cell Transplants Given Myeloablative Regimens Including Pretransplant Antithymocyte Globulin Have Lower.
Chemomobilization with Etoposide is Highly Effective in Patients with Multiple Myeloma and Overcomes the Effects of Age and Prior Therapy  William A.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
In Memoriam: E. Donnall Thomas
Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  Andy I. Chen, Alex McMillan,
Donald R. Dengel, Aaron S. Kelly, Lei Zhang, Qi Wang, James S
Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective.
Presentation transcript:

Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial  Christopher Parrish, Curly T.C.M. Morris, Cathy D. Williams, David A. Cairns, Jamie Cavenagh, John A. Snowden, John Ashcroft, Jim Cavet, Hannah Hunter, Jenny M. Bird, Anna Chalmers, Julia M. Brown, Kwee Yong, Steve Schey, Sally Chown, Gordon Cook  Biology of Blood and Marrow Transplantation  Volume 22, Issue 6, Pages 1009-1016 (June 2016) DOI: 10.1016/j.bbmt.2016.01.016 Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Trial CONSORT Diagram. A full consort diagram for the trial is published (Cook et al. [17]). SD indicates stable disease; PD, progressive disease. Biology of Blood and Marrow Transplantation 2016 22, 1009-1016DOI: (10.1016/j.bbmt.2016.01.016) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Mobilization regimens employed and percentage of mobilization attempts leading to successful PBSC harvest at first, second, and third mobilization attempts. Error bars show 95% confidence intervals. Biology of Blood and Marrow Transplantation 2016 22, 1009-1016DOI: (10.1016/j.bbmt.2016.01.016) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Kaplan-Meier curves after ASCT for patients receiving PBSC harvested before trial entry (PBSC1), reharvested in the trial (PBSC2), and a combination of both sources (PBSCMix). Biology of Blood and Marrow Transplantation 2016 22, 1009-1016DOI: (10.1016/j.bbmt.2016.01.016) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.